Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?. Issue 4 (8th May 2022)

• Record Type: Journal Article
• Authors: Goedhart, Tine M.H.J.; Bukkems, Laura H.; van Moort, Iris; Spence, Colin C.; Zwaan, Michel C.; de Maat, Moniek P.M.; Mathôt, Ron A.A.; Cnossen, Marjon H.
• Is Part Of: Haemophilia. Volume 28:Issue 4(2022)
• Page Start: 610
• Page End: 618
• Publication Date: 2022-05-08
• Subjects: Bayes Theorem -- factor VIII -- haemophilia A -- pharmacokinetics -- product labelling; Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.14575
• Languages: English
• ISSNs: 1351-8216

Abstract

Abstract: Background: To account for interindividual variability in the pharmacokinetics (PK) of factor concentrates, PK‐guided dosing is increasingly implemented in haemophilia patients. Calculations are based on provided label potency, but legislation allows a potency difference of ±20% between label and actual potency. It is unknown if these differences affect PK guidance. Aim: Explore the effects of potency differences on individual factor VIII (FVIII) PK parameters and the prediction of FVIII trough levels of dosing regimens. Methods: We analyzed individual preoperative PK profiling data from severe and moderate haemophilia A patients included in the OPTI‐CLOT randomized controlled trial. Label and actual potency were compared, with data on potency provided by pharmaceutical companies. For both potencies, individual PK parameters were estimated and concentration‐time curves were constructed by nonlinear mixed‐effects modelling. Finally, we explored the effect of both the identified and the maximum legislated potency difference on predicted FVIII trough levels infused in a low and high dose regimen. Results: In 45/50 included patients, actual potency was higher than its label potency. The median potency difference was 6.0% (range ‐9.2% to 18.4%) and resulted in varying individual PK parameter estimates but practically identical FVIII concentration‐time curves. As expected, predicted FVIII trough levels were linearly correlated to the actual dose. Conclusion: It is not necessary to take potency differences into account when applying PK guidance of FVIII concentrates in haemophilia A patients. However, when the patient is switched to another FVIII batch after PK‐guided dosing, trough levels may deviate ±20% from calculations based on label dose.